News Release

Effect of P2Y12 inhibitors on survival free of organ support among hospitalized patients with COVID-19


Peer-Reviewed Publication

JAMA Network

What The Study Did: In this randomized clinical trial with 562 noncritically ill patients hospitalized for COVID-19, the use of a P2Y12 inhibitor combined with a therapeutic dose of heparin didn’t increase the odds of improvement in organ support-free days over 21 days during hospitalization.

Authors: Jeffrey S. Berger, M.D., M.S., of the NYU Grossman School of Medicine in New York, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.